Hepatitis C News and Research

Latest Hepatitis C News and Research

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

In 2008, the World Health Organization announced a global effort to eradicate malaria, which kills about 800,000 people every year. As part of that goal, scientists are trying to develop new drugs that target the malaria parasite during the stage when it infects the human liver, which is crucial because some strains of malaria can lie dormant in the liver for several years before flaring up.

6 Feb 2015

Howard K. Koh receives CADCA's 2015 National Leadership Award

In recognition of his significant contributions to public health and tobacco prevention, and his long-standing support of community-based drug prevention, Community Anti-Drug Coalitions of America (CADCA) will present Howard K. Koh M.D., M.P.H. with its 2015 National Leadership Award.

5 Feb 2015

Researchers suggest novel concept for developing vaccines against HIV and cancer

A experimental trial has shown successful by inducing serum in mice and has been highly neutralizing towards those ailments.

4 Feb 2015

Trust for America's Health supports President's proposal to end sequestration

The following is a statement from Jeffrey Levi, PhD, executive director of the Trust for America's Health (TFAH) and chair of the Advisory Group on Prevention, Health Promotion, and Integrative and Public Health.

4 Feb 2015

International community funding can significantly reduce cancer deaths in LMICs by 2030

Increased annual international community funding of US$18 billion globally could save three million lives per year by 2030 and many more in succeeding decades,

3 Feb 2015

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer.

2 Feb 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

With President Obama's recent State of the Union speech addressing the launch of a national precision medicine initiative to further tackle cancer and other diseases, a leading immunotherapy expert from Rutgers Cancer Institute of New Jersey weighs in on where we stand with precision immunology and personalized medicine and what needs to be accomplished.

30 Jan 2015

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest’s national testing database.

From Quest Diagnostics 29 Jan 2015

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report.

28 Jan 2015

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.

28 Jan 2015

Long-term TDF therapy offers sustained HBV suppression without resistance

Patients with chronic hepatitis B virus infection can achieve sustained viral suppression with long-term tenofovir disoproxil fumarate treatment without developing resistance, shows a 7-year study.

28 Jan 2015

Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest's national testing database.

From Quest Diagnostics 28 Jan 2015

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.

23 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Researchers used spatial analysis software and electronic medical records to identify clusters of underimmunization and vaccine refusal among Kaiser Permanente members in Northern California, according to a study published today in the journal Pediatrics.

19 Jan 2015

Increase in Lassa fever cases could be due to human-to-human transmission, research reveals

One in five cases of Lassa fever - a disease that kills around 5,000 people a year in West Africa - could be due to human-to-human transmission, with a large proportion of these cases caused by 'super-spreaders', according to research published today in the journal PLOS Neglected Tropical Diseases.

16 Jan 2015

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.

16 Jan 2015

European countries implement ATOME project to study improved access to essential painkillers

Governments in 12 European countries are to implement the recommendations of research into why more patients are not receiving essential painkillers.

15 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

Howard K. Koh receives CADCA's 2015 National Leadership Award

Researchers suggest novel concept for developing vaccines against HIV and cancer

Trust for America's Health supports President's proposal to end sequestration

International community funding can significantly reduce cancer deaths in LMICs by 2030

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Long-term TDF therapy offers sustained HBV suppression without resistance

Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Increase in Lassa fever cases could be due to human-to-human transmission, research reveals

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

European countries implement ATOME project to study improved access to essential painkillers

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in